万联晨会-20260108

Market Overview - The A-share market experienced a slight increase on Wednesday, with the Shanghai Composite Index rising by 0.05% to close at 4085.77 points, and the Shenzhen Component Index increasing by 0.06% [1][7] - The total trading volume in the Shanghai and Shenzhen markets reached 2.85 trillion yuan [1][7] - In terms of industry performance, coal, electronics, and telecommunications sectors led the gains, while oil and petrochemicals, non-bank financials, and beauty care sectors lagged [1][7] - Concept sectors such as photoresists, newly listed technology stocks, and storage chips saw increases, while DRG, internet insurance, and brain-computer interface sectors declined [1][7] - The Hong Kong market saw the Hang Seng Index drop by 0.94% to 26458.95 points, and the Hang Seng Tech Index fell by 1.49% [1][7] Important News - The Ministry of Industry and Information Technology and eight other departments issued the "Implementation Opinions on the Special Action of 'Artificial Intelligence + Manufacturing'", aiming for key AI technologies to achieve reliable supply by 2027, with a focus on high-level intelligent computing infrastructure [2][8] - The State Administration for Market Regulation and the National Internet Information Office jointly released the "Supervision and Management Measures for Live E-commerce", targeting issues such as false marketing and counterfeit products in the live e-commerce sector [2][8] Industry Insights - In 2025, the FDA approved 46 new drugs, marking a decline in the number of approvals compared to 2024 and 2023, but the types of approved drugs were diverse and highly innovative [9][10] - The majority of the new drugs approved by the FDA in 2025 were focused on oncology, covering various solid tumors and hematological malignancies, with 34 new drugs undergoing special review processes [10] - Major multinational pharmaceutical companies led in new drug approvals, with notable approvals from Merck, Eli Lilly, Boehringer Ingelheim, and GlaxoSmithKline, while domestic companies like Zhongshan Kanfang Biopharmaceutical and Jiangsu Dize Pharmaceutical also received FDA approvals [10] - Investment recommendations suggest focusing on cutting-edge technology platforms, particularly those with ADC, siRNA, and cell gene therapy capabilities, and companies with global competitive research pipelines [10][12]